P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer

L. M. Dillon, J. R. Bean, W. Yang, K. Shee, L. K. Symonds, J. M. Balko, W. H. McDonald, S. Liu, A. M. Gonzalez-Angulo, Gordon Mills, C. L. Arteaga, T. W. Miller

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Phosphatidylinositol 3-kinase (PI3K) promotes cancer cell survival, migration, growth and proliferation by generating phosphatidylinositol 3,4,5-trisphosphate (PIP 3) in the inner leaflet of the plasma membrane. PIP 3 recruits pleckstrin homology domain-containing proteins to the membrane to activate oncogenic signaling cascades. Anticancer therapeutics targeting the PI3K/AKT/mTOR (mammalian target of rapamycin) pathway are in clinical development. In a mass spectrometric screen to identify PIP 3 -regulated proteins in breast cancer cells, levels of the Rac activator PIP 3 -dependent Rac exchange factor-1 (P-REX1) increased in response to PI3K inhibition, and decreased upon loss of the PI3K antagonist phosphatase and tensin homolog (PTEN). P-REX1 mRNA and protein levels were positively correlated with ER expression, and inversely correlated with PI3K pathway activation in breast tumors as assessed by gene expression and phosphoproteomic analyses. P-REX1 increased activation of Rac1, PI3K/AKT and MEK/ERK signaling in a PTEN-independent manner, and promoted cell and tumor viability. Loss of P-REX1 or inhibition of Rac suppressed PI3K/AKT and MEK/ERK, and decreased viability. P-REX1 also promoted insulin-like growth factor-1 receptor activation, suggesting that P-REX1 provides positive feedback to activators upstream of PI3K. In support of a model where PIP 3 -driven P-REX1 promotes both PI3K/AKT and MEK/ERK signaling, high levels of P-REX1 mRNA (but not phospho-AKT or a transcriptomic signature of PI3K activation) were predictive of sensitivity to PI3K inhibitors among breast cancer cell lines. P-REX1 expression was highest in estrogen receptor-positive breast tumors compared with many other cancer subtypes, suggesting that neutralizing the P-REX1/Rac axis may provide a novel therapeutic approach to selectively abrogate oncogenic signaling in breast cancer cells.

Original languageEnglish (US)
Pages (from-to)3968-3976
Number of pages9
JournalOncogene
Volume34
Issue number30
DOIs
StatePublished - Jul 23 2015
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinase
Growth Factor Receptors
Mitogen-Activated Protein Kinase Kinases
Breast Neoplasms
Phosphoric Monoester Hydrolases
Cell Survival
Somatomedin Receptors
Neoplasms
Messenger RNA
Critical Pathways
Sirolimus
Estrogen Receptors
Cell Movement
Membrane Proteins
Proteins

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Dillon, L. M., Bean, J. R., Yang, W., Shee, K., Symonds, L. K., Balko, J. M., ... Miller, T. W. (2015). P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. Oncogene, 34(30), 3968-3976. https://doi.org/10.1038/onc.2014.328

P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. / Dillon, L. M.; Bean, J. R.; Yang, W.; Shee, K.; Symonds, L. K.; Balko, J. M.; McDonald, W. H.; Liu, S.; Gonzalez-Angulo, A. M.; Mills, Gordon; Arteaga, C. L.; Miller, T. W.

In: Oncogene, Vol. 34, No. 30, 23.07.2015, p. 3968-3976.

Research output: Contribution to journalArticle

Dillon, LM, Bean, JR, Yang, W, Shee, K, Symonds, LK, Balko, JM, McDonald, WH, Liu, S, Gonzalez-Angulo, AM, Mills, G, Arteaga, CL & Miller, TW 2015, 'P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer', Oncogene, vol. 34, no. 30, pp. 3968-3976. https://doi.org/10.1038/onc.2014.328
Dillon, L. M. ; Bean, J. R. ; Yang, W. ; Shee, K. ; Symonds, L. K. ; Balko, J. M. ; McDonald, W. H. ; Liu, S. ; Gonzalez-Angulo, A. M. ; Mills, Gordon ; Arteaga, C. L. ; Miller, T. W. / P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. In: Oncogene. 2015 ; Vol. 34, No. 30. pp. 3968-3976.
@article{6456d232bacf4d49839c6a81d07c7342,
title = "P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer",
abstract = "Phosphatidylinositol 3-kinase (PI3K) promotes cancer cell survival, migration, growth and proliferation by generating phosphatidylinositol 3,4,5-trisphosphate (PIP 3) in the inner leaflet of the plasma membrane. PIP 3 recruits pleckstrin homology domain-containing proteins to the membrane to activate oncogenic signaling cascades. Anticancer therapeutics targeting the PI3K/AKT/mTOR (mammalian target of rapamycin) pathway are in clinical development. In a mass spectrometric screen to identify PIP 3 -regulated proteins in breast cancer cells, levels of the Rac activator PIP 3 -dependent Rac exchange factor-1 (P-REX1) increased in response to PI3K inhibition, and decreased upon loss of the PI3K antagonist phosphatase and tensin homolog (PTEN). P-REX1 mRNA and protein levels were positively correlated with ER expression, and inversely correlated with PI3K pathway activation in breast tumors as assessed by gene expression and phosphoproteomic analyses. P-REX1 increased activation of Rac1, PI3K/AKT and MEK/ERK signaling in a PTEN-independent manner, and promoted cell and tumor viability. Loss of P-REX1 or inhibition of Rac suppressed PI3K/AKT and MEK/ERK, and decreased viability. P-REX1 also promoted insulin-like growth factor-1 receptor activation, suggesting that P-REX1 provides positive feedback to activators upstream of PI3K. In support of a model where PIP 3 -driven P-REX1 promotes both PI3K/AKT and MEK/ERK signaling, high levels of P-REX1 mRNA (but not phospho-AKT or a transcriptomic signature of PI3K activation) were predictive of sensitivity to PI3K inhibitors among breast cancer cell lines. P-REX1 expression was highest in estrogen receptor-positive breast tumors compared with many other cancer subtypes, suggesting that neutralizing the P-REX1/Rac axis may provide a novel therapeutic approach to selectively abrogate oncogenic signaling in breast cancer cells.",
author = "Dillon, {L. M.} and Bean, {J. R.} and W. Yang and K. Shee and Symonds, {L. K.} and Balko, {J. M.} and McDonald, {W. H.} and S. Liu and Gonzalez-Angulo, {A. M.} and Gordon Mills and Arteaga, {C. L.} and Miller, {T. W.}",
year = "2015",
month = "7",
day = "23",
doi = "10.1038/onc.2014.328",
language = "English (US)",
volume = "34",
pages = "3968--3976",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "30",

}

TY - JOUR

T1 - P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer

AU - Dillon, L. M.

AU - Bean, J. R.

AU - Yang, W.

AU - Shee, K.

AU - Symonds, L. K.

AU - Balko, J. M.

AU - McDonald, W. H.

AU - Liu, S.

AU - Gonzalez-Angulo, A. M.

AU - Mills, Gordon

AU - Arteaga, C. L.

AU - Miller, T. W.

PY - 2015/7/23

Y1 - 2015/7/23

N2 - Phosphatidylinositol 3-kinase (PI3K) promotes cancer cell survival, migration, growth and proliferation by generating phosphatidylinositol 3,4,5-trisphosphate (PIP 3) in the inner leaflet of the plasma membrane. PIP 3 recruits pleckstrin homology domain-containing proteins to the membrane to activate oncogenic signaling cascades. Anticancer therapeutics targeting the PI3K/AKT/mTOR (mammalian target of rapamycin) pathway are in clinical development. In a mass spectrometric screen to identify PIP 3 -regulated proteins in breast cancer cells, levels of the Rac activator PIP 3 -dependent Rac exchange factor-1 (P-REX1) increased in response to PI3K inhibition, and decreased upon loss of the PI3K antagonist phosphatase and tensin homolog (PTEN). P-REX1 mRNA and protein levels were positively correlated with ER expression, and inversely correlated with PI3K pathway activation in breast tumors as assessed by gene expression and phosphoproteomic analyses. P-REX1 increased activation of Rac1, PI3K/AKT and MEK/ERK signaling in a PTEN-independent manner, and promoted cell and tumor viability. Loss of P-REX1 or inhibition of Rac suppressed PI3K/AKT and MEK/ERK, and decreased viability. P-REX1 also promoted insulin-like growth factor-1 receptor activation, suggesting that P-REX1 provides positive feedback to activators upstream of PI3K. In support of a model where PIP 3 -driven P-REX1 promotes both PI3K/AKT and MEK/ERK signaling, high levels of P-REX1 mRNA (but not phospho-AKT or a transcriptomic signature of PI3K activation) were predictive of sensitivity to PI3K inhibitors among breast cancer cell lines. P-REX1 expression was highest in estrogen receptor-positive breast tumors compared with many other cancer subtypes, suggesting that neutralizing the P-REX1/Rac axis may provide a novel therapeutic approach to selectively abrogate oncogenic signaling in breast cancer cells.

AB - Phosphatidylinositol 3-kinase (PI3K) promotes cancer cell survival, migration, growth and proliferation by generating phosphatidylinositol 3,4,5-trisphosphate (PIP 3) in the inner leaflet of the plasma membrane. PIP 3 recruits pleckstrin homology domain-containing proteins to the membrane to activate oncogenic signaling cascades. Anticancer therapeutics targeting the PI3K/AKT/mTOR (mammalian target of rapamycin) pathway are in clinical development. In a mass spectrometric screen to identify PIP 3 -regulated proteins in breast cancer cells, levels of the Rac activator PIP 3 -dependent Rac exchange factor-1 (P-REX1) increased in response to PI3K inhibition, and decreased upon loss of the PI3K antagonist phosphatase and tensin homolog (PTEN). P-REX1 mRNA and protein levels were positively correlated with ER expression, and inversely correlated with PI3K pathway activation in breast tumors as assessed by gene expression and phosphoproteomic analyses. P-REX1 increased activation of Rac1, PI3K/AKT and MEK/ERK signaling in a PTEN-independent manner, and promoted cell and tumor viability. Loss of P-REX1 or inhibition of Rac suppressed PI3K/AKT and MEK/ERK, and decreased viability. P-REX1 also promoted insulin-like growth factor-1 receptor activation, suggesting that P-REX1 provides positive feedback to activators upstream of PI3K. In support of a model where PIP 3 -driven P-REX1 promotes both PI3K/AKT and MEK/ERK signaling, high levels of P-REX1 mRNA (but not phospho-AKT or a transcriptomic signature of PI3K activation) were predictive of sensitivity to PI3K inhibitors among breast cancer cell lines. P-REX1 expression was highest in estrogen receptor-positive breast tumors compared with many other cancer subtypes, suggesting that neutralizing the P-REX1/Rac axis may provide a novel therapeutic approach to selectively abrogate oncogenic signaling in breast cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=84937967918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937967918&partnerID=8YFLogxK

U2 - 10.1038/onc.2014.328

DO - 10.1038/onc.2014.328

M3 - Article

C2 - 25284585

AN - SCOPUS:84937967918

VL - 34

SP - 3968

EP - 3976

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 30

ER -